Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Avalo Therapeutics ( (AVTX) ) just unveiled an update.
Avalo Therapeutics has appointed Jennifer Riley as Chief Strategy Officer, effective January 1, 2025, to lead corporate strategy and product pipeline planning. This strategic move aims to enhance Avalo’s growth and innovation, particularly advancing its lead asset, AVTX-009, in the LOTUS Phase 2 trial for hidradenitis suppurativa, and potentially expanding into other inflammatory market opportunities.
More about Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation. Its primary products include AVTX-009, an anti-IL-1β monoclonal antibody aimed at inflammatory diseases, along with two other drug candidates: quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Average Trading Volume: 80,264
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $77.74M
See more insights into AVTX stock on TipRanks’ Stock Analysis page.
